Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
47.00    -1.00 (-2.08%)
Bid:
46.50
Ask:
47.50
Spread: 1.00 (2.151%)
Market Cap: £90.17m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Corporate Update

18 Jan 2016 07:00

RNS Number : 1092M
Iofina PLC
18 January 2016
 

 

18 January 2016

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Corporate Update

Annualised iodine production increase of over 73%

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, today provides an update to the market regarding record crystalline iodine production totals in 2015.

 

During the period, Iofina produced a total of 569.1 metric tonnes ("MT") of crystalline iodine (2014: 327.7MT) from its IOsorb® plants. Although the Company experienced power outages at its IOsorb® plants and at its partners' operations due to adverse weather conditions in late December, resulting in a loss of anticipated production of about 5-7MT of crystalline iodine in the month, the Board is pleased with the like-for-like increase of over 73% of crystalline iodine from our IOsorb® facilities in its core area in Oklahoma.

 

As previously stated, restrictions of particular Salt Water Disposal wells ("SWD") due to seismic activity has marginally impacted the Company's total brine supply. The Company is developing alternatives to mitigate risk associated with potential future restrictions of individual SWDs. The Board's aim is to not only limit risk exposure, but increase the available brine supply to Iofina's IOsorb® plants. Iofina is working with its partners on strategic plans to reduce risk and potentially expand brine supply and the Board looks forward to updating the market in due course.

 

Under current operating conditions, Iofina expects to produce 250-270MT of crystalline iodine in H1 2016 from its five existing IOsorb® plants. This production estimated range is based on the current injection restrictions at certain sites. Again, the Company is working closely with its partners to mitigate and possibly eliminate these flow restrictions.

 

Iofina continues to consume a large amount of its produced iodine through its halogen derivatives division, Iofina Chemical ("IC"). Iodine use at IC was at record levels for the Company in 2015. The Company is encouraged to report that it has successfully marketed and sold significant quantities of IOsorb® produced iodine into the global market place. In line with other commodities in the global market, the price for iodine has continued to soften. Iodine worldwide is generally sold in US Dollars. The strengthening of the US Dollar versus other global currencies has further impacted iodine pricing.

 

In order to manage the impact of these extraneous fluctuations, the Company has successfully cut expenses, reduced production and corporate costs and continues to investigate additional cost cutting measures. These measures are expected to protect the Company's cash position and have a positive impact on the Company's gross margins for the current financial year as it moves toward cashflow positive operations.

 

 

 

 

Commenting, President and CEO Dr. Tom Becker, stated: 

 

"While the Board is encouraged by the sizeable year-on-year iodine production increase and overall operational gains, with the backdrop of an uncertain capital markets and commodity climate, 2016 will be a year of prudency and value protection. The Company remains focused on seeking out ways to streamline efficiencies and mitigate risk, while expanding production at its current plants and future operations." 

 

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Scott

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Dominic Barretto/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7768 537 739

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDBCGBBGLR
Date   Source Headline
9th Oct 20137:00 amRNSOperational Update
2nd Oct 20132:40 pmRNSHolding(s) in Company
26th Sep 20133:32 pmRNSHolding(s) in Company
25th Sep 20137:00 amRNSHalf Yearly Report
19th Sep 20137:00 amRNSDirectorate Change
6th Sep 20137:00 amRNSNotice of Results
16th Aug 20137:00 amRNSBoard Appointment
2nd Aug 20138:30 amRNSIOSorb Patent Awarded
1st Aug 20137:00 amRNSOperational Update
4th Jul 20138:56 amRNSDirector/PDMR Shareholding
3rd Jul 20135:40 pmRNSChange of Registered Office
28th Jun 20132:05 pmRNSDirector/PDMR Shareholding
25th Jun 20138:15 amRNSProduction & Produced Water Congress 2013
24th Jun 20132:22 pmRNSHolding(s) in Company
24th Jun 201312:00 pmRNSResponse to Share Price Movement
19th Jun 20132:10 pmRNSResult of AGM
19th Jun 20137:00 amRNSAGM Statement
17th Jun 20135:01 pmRNSHolding(s) in Company
12th Jun 201310:08 amRNSBoard Changes
5th Jun 20137:00 amRNSPosting of Annual Report and Notice of AGM
20th May 20137:00 amRNSCompletion of US$15m Convertible Bond Issue
8th May 20137:00 amRNSSuccessful Arrangement of US$15m Convertible Bond
7th May 20137:00 amRNSFinal Results
2nd May 20137:00 amRNSChange in Reporting Currency
29th Apr 20137:47 amRNSNotice of Final Results
29th Apr 20137:00 amRNSAtlantis Water Project Update
17th Apr 20137:00 amRNSHolding(s) in Company
15th Apr 20137:00 amRNSBoard Update
3rd Apr 20135:30 pmRNSHolding(s) in Company
28th Mar 20137:55 amRNSAtlantis Water Project
27th Mar 20134:09 pmRNSHolding(s) in Company
11th Mar 20135:19 pmRNSHolding(s) in Company
7th Mar 20137:00 amRNSOperational Update
11th Feb 20131:34 pmRNSHolding(s) in Company
16th Jan 20137:00 amRNSHolding(s) in Company
14th Jan 20137:00 amRNSAppointment of Non-Executive Director
11th Jan 20137:00 amRNSCommissioning of IO#2 IOsorbT Plant
20th Dec 20128:12 amRNSHolding(s) in Company
18th Dec 20129:00 amRNSHolding(s) in Company
4th Dec 20127:00 amRNSProduction Update
17th Sep 20127:00 amRNSHalf Yearly Report
6th Sep 20127:00 amRNSNotice of Results
16th Aug 20127:00 amRNSCommissioning of Plant
31st Jul 20127:00 amRNSCompletion of Construction of IO#1 IOsorb Plant
20th Jun 20122:25 pmRNSResult of AGM
20th Jun 20127:00 amRNSPurchase of Iodine Extraction Facility
7th Jun 20127:00 amRNSHolding(s) in Company
25th May 20127:00 amRNSPlacing to raise £4.3 million
25th May 20127:00 amRNSFinal Results
19th Apr 20127:56 amRNSAppointment of Investec as Nomad and Sole Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.